Adriana Carrillo-Iregui
Pediatric Endocrinology · Miami, FLNPI 1518994524
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 26.4% of the total. 2025 is the largest year on record at $9,164, 5.5 times the $1,679 reported in 2019.
Across 260 payments — averaging $72.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$5K
- Sanofi$3K
- Mannkind Corporation$2K
- Janssen Research & Development, LLC$1K
- Novo Nordisk$942
- Insulet Corporation$865
- plus $6K from 33 others
Across 16 payments — averaging $3771.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$40K
- Janssen Research & Development, LLC$19K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$4,98326%
- Speaking & faculty fees$4,04521%
- Travel & lodging$1,1146%
- Food & beverage$8,57145%
- Education$1371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 22 | $4,973 |
| Sanofi | 2 | $2,975 |
| Mannkind Corporation | 1 | $2,125 |
| Janssen Research & Development, LLC | 5 | $1,238 |
| Novo Nordisk | 28 | $942 |
| Insulet Corporation | 27 | $865 |
| BETA Bionics, Inc. | 12 | $701 |
| Ascendis Pharma Endocrinology Inc | 8 | $692 |
| Tandem Diabetes Care, Inc. | 16 | $635 |
| AbbVie | 24 | $412 |
| Neurocrine Biosciences, Inc. | 5 | $394 |
| Sequel Med Tech, LLC | 4 | $298 |
| Xeris Pharmaceuticals, Inc. | 14 | $279 |
| Pfizer | 10 | $268 |
| AstraZeneca | 6 | $234 |
| Abbott | 9 | $205 |
| Azurity Pharmaceuticals, Inc. | 3 | $145 |
| Dexcom, Inc. | 8 | $144 |
| Rhythm Pharmaceuticals, Inc. | 4 | $140 |
| Ultragenyx Pharmaceutical Inc. | 1 | $125 |
| Lilly USA, LLC | 6 | $118 |
| Lifescan, Inc. | 6 | $107 |
| Eton Pharmaceuticals, Inc. | 2 | $102 |
| Amneal Pharmaceuticals LLC | 6 | $100 |
| Tolmar Pharmaceuticals, Inc. | 4 | $88 |
| Zealand Pharma US, Inc. | 4 | $82 |
| Kyowa Kirin, Inc. | 3 | $71 |
| Biomarin Pharmaceutical Inc. | 3 | $69 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Amryt Pharma Holdings Ltd | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| IBSA Pharma Inc. | 2 | $33 |
| Medtronic | 2 | $30 |
| Embecta Corp. | 1 | $24 |
| Tolmar, Inc. | 1 | $23 |
| Companion Medical, Inc. | 1 | $21 |
| Endo USA, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$3,334
- AFREZZA$2,125
- iLet Bionic Pancreas$1,692
- SKYTROFA$488
- Omnipod$425
- TWIIST$265
- Sogroya$262
- t:slim X2 Insulin Pump with Control-IQ$220
- CRENESSITY$154
- Yorvipath$145
- iLet Insulin Infusion Kit Inset$133
- iLet Insulin Infusion Kit Contact Detach$133
- CRYSVITA$125
- Triptodur$110
- Strensiq$105
How this compares
$18,851 in reported general payments places this provider in the 80th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Miami
- Alejandro DiazMiami$101K
- Andrea GranadosMiami$19K
- Janine SanchezMiami$18K
- Joshua TarkoffMiami$9K
- Luis Gonzalez-MendozaMiami$9K
- Omar BeckettMiami$4K
- Pedro Pagan BanchsMiami$4K
- Carmen Bustamante EscobarMiami$3K
- Jonanlis Ramirez AlcantaraMiami$2K
- Marco DanonMiami$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.